As one of the few pharmaceutical companies in China with a track record in product acquisitions and in-licensing, with our deep market insights, we have been able to successfully identify and acquire or in-license high quality products that address unmet medical needs in China.

Vascepa is a single-molecule product. It is a highly purified omega-3 fatty acid (EPA) ethyl ester. Corroborative clinical trials show that in addition to lowering TG, Vascepa can be used to reduce total cholesterol, non-high-density lipoprotein cholesterol (LC) and very-low-density LC without increasing low-density LC. 

Exploratory studies show that Vascepa can help negatively affect the various mechanisms of atherosclerosis plaque formation, such as by improving lipid oxidation, reducing the level of inflammation, and stabilizing vascular intima. Antithrombotic function. The newly released EVAPORATE study is an imaging study exploring the cardiovascular protection mechanism of Vascepa. The study results show that Vascepa can help stabilize and reverse vulnerable plaques. These MoAs further demonstrate that Vascepa can help protect cardiovascular health in addition to lowering TG.

We expect to launch Vascepa in China in 2022.

Mulpleta(Lusutrombopag) is an innovative thrombopoietin receptor agonist (TPO-RA) that has received approval in Japan, the U.S. and the EU. Mulpleta is indicated for the treatment of thrombocytopenia (TCP) in adult patients with chronic liver disease (CLD) who are scheduled to undergo a surgical procedure.


We expect to launch Mulpleta in China in 2022.

EDP125(Edivoxetine) is an innovative selective norepinephrine reuptake inhibitor (“sNRI”) used to treat ADHD. We Started a Phase III clinical trial for EDP 125 indicated for the treatment of ADHD in children and adolescents in 2022.

Unit 122-129, Building A3 No.700, Wanrong Road,Shanghai

publication@eddingpharm.com

沪ICP备2021007464号

Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038